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Abstract
In our previous studies, ZKSCAN3 was demonstrated to be over-expressed in invasive colonic
tumor cells and their liver metastases, but minimally expressed in adjacent non-transformed
tissues. Further preliminary data showed that ZKSCAN3 was expressed in a majority of prostate
cancer patient samples, but not in normal prostate tissues. Moreover, the ZKSCAN3 protein is
highly expressed in the PC3 prostate cancer cell line, which has high metastatic potential, but little
expression was observed in non-metastatic prostate cancer cell lines. Thus, we hypothesized that
ZKSCAN3 could participate in tumor metastasis by regulating tumor cell migration. To test this
hypothesis, ZKSCAN3 mRNA was knocked down by ZKSCAN3 specific shRNA in PC3 cells
and a significant decrease in cell motility was observed. In contrast, when ZKSCAN3 cDNA was
overexpressed in PC3 cells, cell detachment was observed and suspension culture induced
apoptosis was greatly decreased, suggesting that ZKSCAN3 is able to enhance PC3 cell survival
under anoikis stress. Additional wound healing and invasion assays showed that cell migration
was enhanced by ZKSCAN3 expression. Interestingly, the ZKSCAN3 gene was amplified in 26%
(5/19) of metastatic prostate cancers and 20% (1/5) of lymph node metastases, but there was no
amplification found in primary prostate cancers, further supporting the role of ZKSCAN3 in tumor
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cell migration. In vivo studies using orthotopic tumor models indicated that overexpression of
ZKSCAN3 significantly enhanced tumorigenicity. Taken together, we provide evidence that
ZKSCAN3, a zinc finger transcription factor, plays a critical role in promoting prostate cancer cell
migration.
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1. Introduction
Prostate cancer is a major health problem in the United States, with over 200,000 new cases
diagnosed each year and approximately 30,000 deaths per year (Howlader et al., 2011).
Despite an increased awareness of the disease, which has led to earlier detection and
treatment of the primary tumor, many patients still die of metastases that are resistant to
conventional therapies, including hormonal ablation (Tu and Lin, 2004, Taylor et al., 2006).
Improving the therapy for metastatic prostate cancer now depends on improving our
understanding of the biology of this disease. Metastasis is a multistep process that includes
detachment of cancer cells from the primary tumor, active migration, adhesion and invasion
of tumor cells into the blood vessels, extravasation and subsequent growth in a distant tissue
(Chambers, 1999). In order to metastasize, cancer cells have to acquire various properties;
these include releasing their normal cell-cell adhesion, producing proteolytic enzymes and
acquiring migratory properties. Several earlier reports demonstrated a correlation between
motility of tumor cells and their metastatic potential (Grimstad, 1987, Stracke et al., 1991).
It was recently shown that the cell surface glycoprotein endoglin is a regulator of cell
adhesion, motility and invasion in human prostate cells (Liu et al., 2002).
In prostate cancer, three genes (KAI1, CD44 and MAPK kinase 4) have been identified that
act as metastasis suppressor genes without affecting primary tumor growth (Kauffman.,
2003). MAPK kinase 4 appears to suppress metastasis by inhibiting cancer cell growth at the
secondary site (Kauffman., 2003). Loss of expression has been demonstrated for all of these
genes during the clinical progression of prostate cancer to metastasis (Hendrix, 2003).
Although progress has been made toward understanding genetic alterations that lead to
prostate cancer cell metastasis, much remains to be learned about how cancer cells acquire
the property of migration, a prerequisite for invasion and metastasis. Identification of the
rate limiting steps of metastasis and their underlying molecular mechanisms may lead to
new therapeutic targets and also allow more accurate risk stratification for clinical
metastases.
Previously, we demonstrated that ZKSCAN3, a novel zinc finger transcription factor, is
overexpressed in colon tumors and multiple myeloma (MM), and activates a gene
expression program driving colon cancer and MM progression (Yang et al., 2008a , Yang et
al., 2011). More importantly, ZKSCAN3 is highly expressed in deep invasive tumor cells
compared to superficial non-invasive tumor cells, suggesting that it plays a very important
role in driving tumor cell migration and invasion (Yang et al., 2008a). Interestingly,
ZKSCAN3 resides on chromosome 6p22.1. The 6p21-23 region is commonly amplified in
multiple solid tumors (Santos et al., 2007, Kallioniemi et al., 1992). Recently, chromosome
6p22 was linked to a high risk pedigree with aggressive prostate cancer (Schaid et al., 2006,
Janer et al., 2003). Thus it is of particular interest to investigate if ZKSCAN3 plays a role in
modulating prostate cancer cell metastasis.
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In this study, we report that ZKSCAN3 is highly expressed in prostate tumor tissues but not
normal adjacent tissues. ZKSCAN3 not only enhanced prostate cancer cell detachment,
motility and migration, but caused a robust induction of tumorigenicity in vivo as well,
supporting a role of ZKSCAN3 in regulating prostate cancer cell migration.
2. MATERIALS AND METHODS
2.1. Array Comparative Genomic Hybridization (aCGH) Analysis
DNA from prostatectomy cases was isolated and prepared as described previously (Paris et
al., 2003). aCGH was performed using BAC arrays containing 2,460 BAC clones printed at
UCSF. The BAC aCGH was performed as described in Paris et al (Paris et al., 2003, Paris et
al., 2007) with a male reference DNA (Promega). Regions of copy number gain and loss for
the BAC aCGH data were identified by creating sample specific thresholds (Paris et al.,
2004).
2.2. Cell culture and Transfections
PC3 and CWR22r cells were kindly provided by Dr Isaiah J Fidler (The University of Texas
M.D. Anderson Cancer Center, Houston, TX, USA), and cultured in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum. Cells were transfected with
Lipofectamine 2000 (as per Invitrogen instructions). Flag-tagged ZKSCAN3 was sub-cloned
into the pIRES2-EGFP bicistronic vector and PC-3 cells were transfected with this Flag-
tagged ZKSCAN3 expression construct. The DNA lipofectamine complex was added to ~
107 cells and after 48 hours, 2 mg/ml G418 was added to select stably-transfected cells.
Knockdown of ZKSCAN3 with ZKSCAN3 specific shRNA was performed according to
previously described procedures (Yang et al., 2011). For transient transfections to identify
optimal shRNA sequences, we used the procedure described by Invitrogen. (http://
www.invitrogen.com-/downloads/HCT116_-stealthrnai_tsf_protocol.pdf).
2.3. Western blotting
ZKSCAN3 protein expression in prostate cancer cell lines was measured by western blotting
(Yang et al., 2008a, Yang et al., 2008b). Cells were harvested and rinsed twice with ice-cold
PBS and homogenized in buffer containing 10 mmol/L Tris-HCl (pH 7.4), 150 mmol/L
NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 5mol/L edetic acid, 1 mmol/
L PMSF, 0.28 U/L aprotinin, 50 mg/L leupeptin, 1 mmol/L benzamidine, 7 mg/L pepstain
A. Protein concentration was determined using the BCA kit (Thermo Scientific Pierce,
Rockford, IL). Thirty micrograms of protein from each sample was subjected to
electrophoresis on a 10-12% SDS-PAGE gel using a constant current. Proteins were
transferred to nitrocellulose membranes and incubated with Tris-buffered saline containing
0.2% Tween-20 (TBST) and 3% nonfat dry milk for 3 hours in the presence of one of the
following antibodies: 0.1 μg/ml of the affinity-purified anti-ZKSCAN3 antibody which was
as described previously (Yang et al., 2008a) or a 1:2000 dilution of the anti-Flag M2
antibody from Sigma-Aldrich (Saint Louis, MO, USA). Membranes were washed and
incubated with horseradish peroxidase (HPR)-conjugated anti-mouse IgG (1:10,000) in
TBST containing 3 % nonfat dry milk for 1 hour. Immunoreactivity was detected with the
Amersham enhanced chemiluminescent (ECL) kit (Amersham, Buckinghamshire, UK)
according to the manufacturer’s instructions.
2.4. Immunohistochemistry
For immunohistochemistry analysis, prostate cancer tissue array slides were purchased from
Biomax US (Catalog number: PR802), in which each tissue microarray contained 78 cases
of prostate carcinoma, 2 cases normal tissue with single core per case. After de-waxing and
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antigen retrieval, endogenous peroxidase was inactivated with H2O2, and slides were
blocked with 5% normal horse serum, 1% normal goat serum. Sections were incubated with
affinity-purified anti-ZKSCAN3 and then with a horseradish peroxidase-conjugated
secondary antibody. Immunoreactivity was detected with the DAB chromogen (Research
Genetics). For negative controls, the anti-ZKSCAN3 antibody was substituted with an
equivalent amount of pre-immune IgG.
Immunoreactivity was quantitated as follows: five independent fields (100 × magnification;
no counterstain) were digitized and immunoreactivity pixel area determined using ImageJ
(v1.34s) software (http://rsb.info.nih.gov/ij/).
2.5. Flow cytometric analysis
For flow cytometric analysis, PC3 cells transfected with shNon-targeting or shZKSCAN3
for 48 hours were trypsinized, washed in PBS, and resuspended in ice-cold 80% ethanol.
Cells were permeabilized with 0.25% Triton X-100, and were then blocked with 10%
normal goat serum (NGS) for 15 min. Cells were incubated with the indicated antibodies:
0.1 μg/ml affinity-purified anti-ZKSCAN3 antibody (Yang et al., 2008a) or the isotype
matched control mineral oil plasmacytoma-10 from Sigma-Aldrich (Saint Louis, MO, USA),
followed by incubation with goat anti-mouse IgG1-FITC (Southern Bio-technology,
Birmingham, AL). All of the staining was done on ice for 45 min followed by three washes
in HBSS + 5% FBS. The stained cells were filtered through the cell strainer caps of Falcon
polystyrene round-bottomed tubes. Fluorescence was analyzed on a Becton Dickinson
FACScan (Becton Dickinson, San Jose, CA). Data were collected from at least 10,000 cells.
Using the Coulter software, the percentage of positive cells and their Mean Fluorescence
Intensity (MFI) were determined by comparison with the isotype matched control stained
cells.
2.6. Cell motility and invasion assays
For the cell motility assay, the upper and lower surfaces of the membrane in transwell
inserts (Costar) were coated with collagen I at 4°C overnight. To prepare for the invasion
assay, Matrigel (Collaborative Research; 0.5 μg) was diluted with cold water and dried onto
each transwell insert overnight at room temperature. On the following day, transwell
membranes were blocked with DMEM for 1 hour at 37°C. Cells were trypsinized and
resuspended in serum-free DMEM. A total of 105 cells were added to the upper chamber of
each well. Lysophosphatidic acid (LPA; 100 ng/mL) was added to the lower chambers as a
chemoattractant. Inserts were incubated for 2 to 3 hours, and non-migrating cells were
mechanically removed with cotton swabs. The cells attached to the bottom side of the
membrane were stained with crystal violet and counted. Assays were done in triplicate and
repeated five times. Cell motility and invasion were quantified by counting the cells that
migrated to the lower surface of the membrane per square milliliter using bright-field optics.
2.7. PC3 cell detachment
PC3-empty-vector and PC3-ZKSCAN3 stably transfected cells were seeded into 24 well
plates at 5×105/well. After 48 hours, the cells were treated with 2mM EDTA for 5 to 25
minutes. After incubation with EDTA, the cells were washed with PBS and then incubated
with (3-(4,5-dimethylthiazol-2-y1)-2,5-diphenyltetrazolium bromide (MTT) reagent diluted
in RPMI medium (5 mg/ml) at 37°C. After 2 hours the formazan crystals produced by
metabolism of MTT in live cells were reconstituted in DMSO. The optical density at 570 nm
was determined using an ELISA reader. The percentage of detached cells was calculated
using this formula: Percentage of detached cells = 100 - [(OD570 of EDTA treated cells) /
(OD570 of untreated cells) × 100%].
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2.8. Cell Migration Assay
Cells were sub-cultured in 6-well plates and incubated in RPMI with 10% FBS. PC3 cells
were transfected with shNon-targeting or shZKSCAN3 for 48 hours and CWR22r cells were
transfected with empty-vector or ZKSCAN3 for 48 hours. A 1 mm thick wound was created
using a 10 μL micropipette tip. Cells were washed and incubated in serum free medium.
Cell migration was monitored and photographed after a 24 hour incubation.
2.9. Intraprostatic Injection of PC3 Cells
Two independent PC3 cell clones stably overexpressing ZKSCAN3 (PC3-ZKSCAN3#1 and
PC3-ZKSCAN3#2) and PC3 cells stably transfected with the empty vector were harvested
from subconfluent cultures and resuspended in Ca2+- and Mg2+-free Hanks’ balanced salt
solution (HBSS). Cell viability was determined by Trypan Blue dye exclusion and only
single-cell suspensions of >95% viability were used to inject mice. Three groups of nude
mice (5 mice/group) were anesthetized with Nembutal (0.5 mg/g body weight) (Abbott
Laboratories, North Chicago, IL), and intraprostatic injection of 25 μL/mouse of cell
suspension (1×105 cells) from either empty vector or Flag-ZKSCAN3 cDNA was performed
as described previously (Yang et al., 2008b). The animals tolerated the surgical procedure
well, and no anesthesia-related deaths occurred. After 4 weeks mice were sacrificed, and
tumors were circumscribed, surgically removed, and weighed by electronic balance. The
abovementioned experiments were repeated three times. All experiments were approved by
the Institutional Animal Care and Use Committee.
2.10. Cell cycle assays
For flow cytometric analysis, PC3 cells stably transfected with empty vector or ZKSCAN3
for 48 hours were trypsinized, washed in PBS, and resuspended in ice-cold 80% ethanol.
Briefly, 2.5×105 fixed cells were incubated in 250 μL propidium iodide solution (500 mg/
mL propidium iodide in 3.8 mol/L sodium citrate at pH 7.0) and 250 μL RNase A (10 mg/
mL prepared in 10 mmol/L Tris-HCl at pH 7.5) for 30 minutes at 37°C in the dark. The
stained cells were filtered through the cell strainer caps of Falcon polystyrene round-
bottomed tubes. DNA content was analyzed on a Becton Dickinson FACScan (Becton
Dickinson, San Jose, CA). Percent cell cycle phase was determined using Cell Fit software
(Becton Dickinson). Data were collected from at least 20,000 cells.
3. RESULTS
3.1. ZKSCAN3 is overexpressed in prostate tumors
Because the ZKSCAN3 gene has been shown to be amplified in colon cancer and multiple
myeloma cells, we investigated whether the ZKSCAN3 gene was amplified in prostate
cancer as well. ZKSCAN3 was mapped to the BAC clone RP11-2P4 on the UCSF array.
aCGH was performed using BAC arrays containing 2,460 BAC clones printed at UCSF, and
regions of copy number gain and loss for the BAC clone RP11-2P4 were identified by
creating sample specific thresholds (Paris et al., 2004). As shown in Fig. 1A, the region for
the ZKSCAN3 gene was amplified in 26% of bone metastatic prostate cancers (5/19) and
20% of lymph node metastases (1/5), and there was no amplification of the ZKSCAN3 gene
observed in primary tumors, suggesting that ZKSCAN3 may play a role in prostate cancer
metastasis.
To demonstrate that the ZKSCAN3 protein is expressed in prostate cancer, we performed
immunohistochemistry (IHC) on a prostate cancer tissue array with an anti-ZKSCAN3
antibody generated during our previous studies (Yang et al., 2008a). While little staining
was seen in normal prostate tissue, 48.7% of tumor tissues (38/78) showed strong reactivity
predominantly localized to the nucleus (Fig. 1B), a pattern similar to many zinc finger-
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containing proteins, supporting the hypothesis that ZKSCAN3 may play an important role in
driving prostate cancer progression.
Since our previous studies suggested that ZKSCAN3 could participate in tumor cell invasion
(Yang et al., 2008a), endogenous ZKSCAN3 protein expression was compared in the
prostate cancer cell lines LNCaP, CWR22r, DU145, and PC3, which represent different
metastatic potentials. Western blot analysis of nuclear extracts from these cell lines
demonstrated that the level of ZKSCAN3 expression correlated with the metastatic potential
of the cell lines, with the highest expression level found in PC3 cells and no detectable
expression in non-metastatic CWR22r cells (Fig. 1C). The DU145 and LNCaP cell lines
expressed ZKSCAN3 at a lower level than PC3 cells, which correlated with their lower
metastatic potential.
3.2. Exogenous expression of ZKSCAN3 increases prostate cancer cell detachment and
motility
Differential expression of ZKSCAN3 in invasive and non-invasive tumor cells suggests a
role for ZKSCAN3 in promoting tumor metastasis (Yang et al., 2008a). It has been
suggested that both the ability of tumor cells to detach as well as an increase in motility are
associated with the development of metastatic potential in prostate cancer. Thus, the next
experiments were designed to determine if ZKSCAN3 participates in the process of prostate
cancer cell detachment and motility. PC3 cells were transfected with a Flag-tagged
ZKSCAN3 expression construct, and transfected cells were selected with 0.5 mg/ml G418.
After 2 weeks, a G418-resistant GFP-positive pool was harvested and analyzed for
ZKSCAN3 expression by Western blotting (Fig. 2A) using the anti-Flag M2 antibody. The
Flag-tagged ZKSCAN3 protein was expressed in the PC3-ZKSCAN3 cell lysate, but not in
the empty-vector transfected PC3 cell lysate.
We next examined the effect of overexpression ZKSCAN3 on PC3 cell proliferation and
found that the proliferation rate of the PC3-ZKSCAN3 cells was similar to that of the PC3-
empty vector cells, suggesting that ZKSCAN3 has little effect on PC3 cell proliferation in
monolayer culture conditions (data not shown). However, we observed that the PC3-
ZKSCAN3 cells were sensitive to incubation with detaching buffer (i.e. 2mM EDTA,
trypsin), suggesting that ZKSCAN3 might have an impact on cell detachment. When 2mM
EDTA was added to PC3 cells that had been adhered for 48 hours to 24 well plates, the PC3-
ZKSCAN3 cells were significantly more sensitive to EDTA-induced detachment than the
PC3-empty vector cells (Fig. 2B).
Since ZKSCAN3 enhanced cell detachment, we next investigated whether ZKSCAN3
regulated cell motility using a transwell migration assay. As shown in Fig.2C, PC3-
ZKSCAN3 cells showed greater motility compared to PC3-empty vector cells. There was a
three fold increase in the number of cells migrating through the membrane in the PC3-
ZKSCAN3 cultures compared to the PC3-empty vector controls.
Because ZKSCAN3 greatly enhanced cell detachment and motility in PC3 cells, we next
studied whether ZKSCAN3 regulated cell migration. CWR22r cells were transfected with
the Flag-tagged ZKSCAN3 expression construct, and expression of Flag-tagged ZKSCAN3
was confirmed by Western blotting (Fig.2D). Wound healing assays were performed by
creating a 1 mm wide wound in a monolayer of CWR22r cells transfected with either Flag-
tagged ZKSCAN3 or empty vector. After 24 hours, CWR22r cells transfected with
ZKSCAN3 had migrated farther than cells transfected with the empty vector (Fig. 2E),
indicating that overexpression of ZKSCAN3 enhanced CWR22r cell migration, even though
the CWR22r cells were originated from a primary xenograft without metastatic potential.
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3.3. ZKSCAN3 knockdown decreases PC3 cell migration
Since expression of ZKSCAN3 enhanced cell migration, we next studied whether
knockdown of ZKSCAN3 could inhibit cell migration. PC3 cells were transfected with
shZKSCAN3, an shRNA construct targeting ZKSCAN3. Flow cytometry was used to detect
the expression of ZKSCAN3 in PC3 cells after treatment with shZKSCAN3 for 48 hours.
ZKSCAN3 protein expression was greatly inhibited by shZKSCAN3 compared to the non-
targeting shRNA control (Fig 3A).
Wound healing assays were performed by creating a 1 mm thick wound in a monolayer of
PC3 cells transfected with either shZKSCAN3 or shNon-targeting vectors. As shown in Fig.
3B, PC3 cells transfected with shZKSCAN3 demonstrated a significantly decreased
migration 24 hours after the wound was created compared to PC3-shNon-targeting cells,
indicating that knockdown of ZKSCAN3 decreased PC3 cell migration.
3.4. Exogenous expression of ZKSCAN3 increases cell cycle progression in suspension-
cultured prostate cancer cells
Our initial observation that overexpression of ZKSCAN3 in PC3 cells cultured in monolayer
did not alter the proliferation rate was unexpected. However, if ZKSCAN3 indeed represents
a critical factor in regulating cell migration, it would be expected to enhance cell viability
and proliferation under conditions of anoikis stress, a situation that can be approximated in
vitro by culturing prostate cancer cells in suspension. To determine if an enhanced cell
proliferation rate contributed to the increased migration ability of the ZKSCAN3 transfected
cells, cell cycle analysis was performed on PC3 cells transfected with ZKSCAN3 and the
empty vector control under cell suspension culture conditions that mimic anoikis in vitro.
When PC3-empty vector cells were grown in suspension culture, about 37% of the cells
apoptotic were found in the sub-G1 portion of the cell cycle profile (Fig 4A). However,
overexpression of ZKSCAN3 in PC3 cells decreased the apoptotic cells to about 12%, and
increased the S phase cell population, suggesting that ZKSCAN3 is able to enhance PC3 cell
survival and proliferation under anoikis stress, further supporting the role of ZKSCAN3 in
regulating prostate cancer migration.
3.5. Effect of ZKSCAN3 on PC3 cell tumor formation in vivo
As migration and motility of tumor cells are prerequisites for the development of prostate
cancer metastasis, and the tumor micro-environment plays a critical role in affecting
tumorigenesis, it is essential to evaluate the role of ZKSCAN3 in vivo with an orthotopic
model. Two independent PC3 cell clones stably overexpressing ZKSCAN3 (PC3-
ZKSCAN3#1 and PC3-ZKSCAN3#2) and PC3 cells stably transfected with the empty
vector were orthotopically injected into nude mice. As expected, ZKSCAN3 caused a robust
induction of tumorigenicity (Fig. 4B) as evidenced by a 2-fold increase in tumor weight four
weeks after injection (Fig. 4C). The weight of the tumors increased from 0.3 ± 0.1g with
PC3-empty vector cells to 0.7 ± 0.3g with PC3-ZKSCAN3(PC3-ZKSCAN3#1 and PC3-
ZKSCAN3#2) cells, and the difference was statistically significant (p<0.05; n = 5).
Statistical comparisons were carried out by ANOVA followed by Dunnett t-test. The
experiment was repeated three times with similar results.Taken together, these data
demonstrate that overexpression of ZKSCAN3 contributes to the tumorigenic phenotype.
4. DISCUSSION
Cancer remains one of the leading causes of death in developed countries. However, much
remains to be learned about the mechanisms controlling cancer cell growth and metastasis,
especially the molecular events in gene regulation in tumor cells that contribute to cancer
metastasis. In our previous studies, we identified the novel zinc finger transcription factor
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ZKSCAN3 as a new driver for colorectal cancer and multiple myeloma progression (Yang et
al., 2008a , Yang et al., 2008b, Yang et al., 2011). In particular, previous studies
demonstrated that ZKSCAN3 is selectively expressed in invasive tumor cells and colon
cancer liver metastases compared to non-invasive tumor cells (Yang et al., 2008a). To
examine the possibility that ZKSCAN3 is involved in regulating tumor metastasis, we first
investigated the impact of ZKSCAN3 on tumor cell migration, a prerequisite for tumor
metastasis. In this work, we demonstrate that the expression level of ZKSCAN3 correlates
with the metastatic potential of the prostate cancer cell lines, with the highest expression
level in PC3 cells, which have high metastatic potential, but no expression in the primary
xenograft derived CWR22r cells. Functional assays showed that knock down of ZKSCAN3
significantly decreased prostate cancer cell migration, while overexpression of ZKSCAN3
enhanced prostate cancer cell detachment in monolayer cultures treated with EDTA and
enhanced survival under suspension culture conditions.
However, the mechanism by which ZKSCAN3 contributes to prostate cancer migration has
not been elucidated. Previous studies from our group determined that ZKSCAN3
coordinated a gene expression program including vascular endothelial growth factor
(VEGF), integrin β4, and cyclin D2; that it was an important “driver” for colon cancer and
multiple myeloma progression; and that its small interfering (si) RNA-mediated down-
regulation slowed tumor growth in vivo (Yang et al., 2011). Gene expression profiling data
showed that EGFR (epidermal growth factor receptor), cyclin D1, NF-κB, MEK2 (mitogen-
activated protein kinase kinase 2), and IGF-2 (insulin-like growth factor-2) may represent
ZKSCAN3 downstream targets as well. Since most of these genes have been demonstrated
to promote tumorigenesis, including cancer metastasis (Ueno et al., 2011, Li et al., 2006, Su
et al., 2010, Suvasini et al., 2011), it would be scientifically significant to further analyze the
gene expression program regulated by ZKSCAN3 during the process of enhancing prostate
cancer cell migration.
Gene amplification could be one of the factors that contribute to increased ZKSCAN3
expression as prostate cancer progresses to a metastatic phenotype because amplification of
the ZKSCAN3 gene was observed in metastatic prostate cancer samples and not in primary
samples. Analysis of prostate cancer patient samples by aCGH array found that the region
closest to ZKSCAN3 was amplified in 26% of metastatic prostate cancer samples (Fig. 1A).
Indeed, our previous studies also observed that the ZKSCAN3 gene was amplified in
colorectal cancer and multiple myeloma (Yang et al., 2008a , Yang et al., 2011), which
contributed to ZKSCAN3 expression in these malignant cells.
In conclusion, we have described ZKSCAN3 as a driver of prostate tumor progression by
modulating cell detachment, migration and motility. Moreover, ZKSCAN3 caused a robust
induction of tumorigenicity in in vivo models. Further investigation of the upstream signal
regulation of ZKSCAN3 will provide new insights into the mechanisms accommodating or
contributing to prostate cancer cell metastasis, thereby unveiling new strategies for tumor
therapy.
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Expression of ZKSCAN3 in primary prostate cancer, metastatic prostate cancer, and prostate
cancer cell lines. A: ZKSCAN3 loci are amplified in metastatic prostate cancer. BAC arrays
were used to detect ZKSCAN3 gene amplification using DNA isolated from primary or
metastatic prostate cancers. The prostate cancers were divided into 5 groups: primaries that
progress to bone (N=12), primaries that progress biochemically (N=32), nonprogressors
(N=32), bone metastases (N=19) and hormone naïve lymph node metastases (N=8). B:
Expression and localization of the ZKSCAN3 protein to the tumor cells in resected prostate
cancer. Normal prostate tissue and 5 different gleasons cancer tissue were arrayed by
immunohistochemistry using the affinity-purified anti-ZKSCAN3 antibody. C: The
expression of ZKSCAN3 in representative prostate cancer cell lines with differential
metastatic potential. ZKSCAN3 expression was analyzed in nuclear extracts from LNCaP,
CWR22r, DU145 and PC3 cells by Western blotting with the anti-ZKSCAN3 antibody.
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Exogenous expression of ZKSCAN3 increases prostate cancer cell detachment and motility.
A: Generation of stable PC3-ZKSCAN3 cell lines. PC3 cells were transfected with the Flag-
tagged ZKSCAN3 expression construct. Cells were selected with 0.5 mg/ml G418 and after
2 weeks, a G418-resistant pool was harvested and analyzed for ZKSCAN3 expression by
Western blotting using the anti-Flag M2 antibody. B: ZKSCAN3 enhanced PC3 cell
detachment. PC3-vector and PC3-ZKSCAN3 stable cells were seeded in 24 well plates.
After 48 hours, the cells were treated with 2mM EDTA for 5 to 25 minutes. The cells were
washed with PBS and then incubated with MTT reagent diluted in RPMI medium (5 mg/ml)
at 37°C for 2 hours. The formazan crystals produced by metabolism of MTT were
reconstituted in DMSO, and the optical density at 570 nm was determined using an ELISA
reader. The percentage of detached cells was calculated using the formula: 100 - [(OD570 of
EDTA treated cells) / (OD570 of untreated cells) × 100%]. C: ZKSCAN3 enhanced PC3 cell
motility in a transwell migration assay. PC3-vector and PC3-ZKSCAN3 stable cells were
added to the upper chamber of each well and allowed to migrate through the collagen coated
membrane for 2 to 3 hours. Cell motility was quantified by counting the cells that migrated
to the lower surface of the membrane per square milliliter using bright-field optics. D:
Overexpression of Flag-tagged ZKSCAN3 was confirmed in CWR22r cells. CWR22r cells
were transfected with the Flag-tagged ZKSCAN3 expression construct, and ZKSCAN3
expression was analyzed by Western blotting using the anti-Flag M2 antibody. E:
Overexpression of ZKSCAN3 enhanced CW22Rr cell migration in a wound healing assay.
CWR22r cells were transfected with empty-vector or ZKSCAN3 for 48 hours. A 1 mm thick
wound was created using a 10 μL micropipette tip, and cell migration was photographed
after 24 hours.
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Knockdown of ZKSCAN3 decreased PC3 cell migration A: The expression of ZKSCAN3 in
PC3 cells was greatly reduced by shZKSCAN3. Flow cytometry analysis was used to detect
ZKSCAN3 expression in PC3 cells treated with shNon-targeting and shZKSCAN3.
Permeabilized cells were stained with either an anti-ZKSCAN3 antibody or an isotype
matched control antibody, followed by anti-mouse IgG1 conjugated to FITC. The expression
of ZKSCAN3 was greatly inhibited by shZKSCAN3 compared to the shNon-targeting
control. B: Knockdown of ZKSCAN3 enhanced PC3 cell migration in a wound healing
assay. PC3 cells were transfected with shNon-targeting control or shZKSCAN3 for 48
hours. A 1 mm thick wound was created using a 10 μL micropipette tip, and cell migration
was photographed after 24 hours.
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Effect of ZKSCAN3 on cell cycle and orthotopic tumor growth. A: Cell cycle profiles were
obtained in PC3 cells transfected with either ZKSCAN3 or the control empty vector by
staining with propidium iodide followed by flow cytometry analysis. A total of 20,000
events were collected from each of three replicate experiments, and cell cycle distributions
were analyzed using Cell Fit software (Becton Dickinson). Statistical comparisons of the
differences in the cell cycle distributions were carried out by ANOVA followed by
Dunnett’s t-test. **p< 0.01 PC3-ZKSCAN3 group vs. PC3-empty vector group. B: Effect of
ZKSCAN3 overexpression on orthotopic tumor growth. PC3 empty vector or PC3
ZKSCAN3 transfected cells (1×105 cells/25μl) were injected into the prostate of each nude
mouse. After 4 weeks mice were sacrificed, and tumors were photographed. The tumors are
circumscribed in the photographs. C: Orthotopic tumors were surgically removed and
weighed.
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